Article Information
History
- October 20, 2021.
Article Versions
- Version 1 (October 7, 2021 - 09:58).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Isobel Routledge1,*,
- Saki Takahashi1,
- Adrienne Epstein1,
- Jill Hakim1,
- Owen Janson1,
- Keirstinne Turcios1,
- Jo Vinden1,2,
- John Tomas Risos3,
- Margaret Rose Baniqued3,
- Lori Pham3,
- Clara Di Germanio4,
- Michael Busch3,4,
- Margot Kushel5,
- Bryan Greenhouse1 and
- Isabel Rodríguez-Barraquer1
- 1Department of Medicine, University of California San Francisco, San Francisco, California, USA
- 2Infectious Disease and Immunity Graduate Group, University of California Berkeley, Berkeley, California, USA
- 3Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA
- 4Vitalant Research Institute, San Francisco, California, USA
- 5Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, USA
- ↵*Corresponding author; email: isobel.routledge{at}ucsf.edu
Posted October 20, 2021.
Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2
